Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma Recruiting Phase 2 Trials for Edralbrutinib (DB18095)

IndicationStatusPhase
DBCOND0140678 (Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04948788SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaTreatment